Technical Analysis for NOVN - Novan, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| See historical NOVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | 50 DMA Resistance | Bearish | 0.00% |
| Jan 16 | Wide Bands | Range Expansion | 0.00% |
| Jan 16 | Upper Bollinger Band Touch | Strength | 0.00% |
| Jan 15 | Wide Bands | Range Expansion | 21.71% |
| Jan 15 | Down 3 Days in a Row | Weakness | 21.71% |
| Jan 14 | Wide Bands | Range Expansion | 20.77% |
| Jan 14 | Overbought Stochastic | Strength | 20.77% |
| Jan 11 | 50 DMA Resistance | Bearish | -1.26% |
| Jan 11 | Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.26% |
| Jan 11 | Upper Bollinger Band Walk | Strength | -1.26% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-08
- Sector: Healthcare
- Industry: Specialty & Advanced Pharmaceuticals
Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NOVN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 3.65 |
| 52 Week Low | 0.65 |
| Average Volume | 104,686 |
| 200-Day Moving Average | 2.542 |
| 50-Day Moving Average | 1.6386 |
| 20-Day Moving Average | 1.1108 |
| 10-Day Moving Average | 1.3245 |
| Average True Range | 0.2317 |
| ADX | 30.18 |
| +DI | 31.0061 |
| -DI | 22.4616 |
| Chandelier Exit (Long, 3 ATRs ) | 1.1349 |
| Chandelier Exit (Short, 3 ATRs ) | 1.3451 |
| Upper Bollinger Band | 1.6858 |
| Lower Bollinger Band | 0.5358 |
| Percent B (%b) | 0.9 |
| BandWidth | 103.528988 |
| MACD Line | -0.0153 |
| MACD Signal Line | -0.1115 |
| MACD Histogram | 0.0962 |
| Fundamentals | Value |
|---|---|
| Market Cap | 25.09 Million |
| Num Shares | 16 Million |
| EPS | -4.08 |
| Price-to-Earnings (P/E) Ratio | -0.38 |
| Price-to-Sales | 129.29 |
| Price-to-Book | 8.46 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.19 | ||||
| Resistance 3 (R3) | 2.16 | 1.92 | 2.08 | ||
| Resistance 2 (R2) | 1.92 | 1.77 | 1.94 | 2.05 | |
| Resistance 1 (R1) | 1.75 | 1.67 | 1.84 | 1.78 | 2.01 |
| Pivot Point | 1.51 | 1.51 | 1.56 | 1.53 | 1.51 |
| Support 1 (S1) | 1.34 | 1.36 | 1.43 | 1.37 | 1.13 |
| Support 2 (S2) | 1.10 | 1.26 | 1.12 | 1.09 | |
| Support 3 (S3) | 0.93 | 1.10 | 1.06 | ||
| Support 4 (S4) | 0.96 |
